The trajectory of companies tied to flagship drugs like Viagra presents a complex investment scenario . While the initial boom of copyright, fueled by Viagra's remarkable popularity, generated substantial returns, the expiry in key territories has introduced substantial volatility. Investors are now grappling with the impact of rival medications ,